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Prevalence of prescribing in pregnancy using the
Irish primary care research network: a pilot study
Paul Dillon*, Kirsty K O’Brien, Ronan McDonnell, Erica Donnelly-Swift, Rose Galvin, Adam Roche, Kate Cronin,
David R Walsh, Rowan Schelten, Susan Smith and Tom Fahey
Abstract
Background: To establish the prevalence and patterns of prescribing to pregnant women in an Irish primary care
setting.
Methods: We reviewed electronic healthcare records routinely collected in primary care, of pregnant women
attending nine Dublin-based General Practices affiliated to the Irish Primary Care Research Network (IPCRN) for
antenatal care between January 2007 and October 2013 (n = 2,361 pregnancies).
Results: Excluding folic acid, 46.8% (n = 1,104) of pregnant women were prescribed at least one medication.
Amoxicillin (11.1%, n = 263) and co-amoxiclav (8.0%, n = 190) were the most commonly prescribed medication
followed by topical clotrimazole (4.9%, n = 117), salbutamol inhalers (4.1%, n = 96) and paracetamol (4.0%, n = 95).
General Medical Services (GMS) patients were more likely to receive a prescription than private patients (OR 2.81;
95%CI (2.28, 3.47)). We applied the US FDA pregnancy-risk categories as a proxy measure of prescribing appropriateness,
with FDA Category D and X medications considered inappropriate. FDA Category D drugs were prescribed in
5.9% (n = 140) of pregnancies. FDA Category X drugs were prescribed in 4.9% (n = 116) of pregnancies but after
exclusion of oral contraceptives, progestogens, infertility treatments Category X medications were prescribed in
0.6% (n = 13) of pregnancies. After the initial antenatal consultation the prescribing prevalence of FDA Category D
medications reduced to 4.7% (n = 110) and Category X to 3.1% (n = 72).
Conclusions: The overall prevalence of prescribing to pregnant women in our cohort is low compared to studies
internationally, however similar levels of prescribing for FDA Category D and X were found. Following the initial
antenatal consultation levels of prescribing of the FDA Category D and X medications reduced, however there is
potential to further reduce their use in early pregnancy. The IPCRN database has provided valuable information
on the current practice of antenatal prescribing within this pilot group of practices however it is limited by the
absence of morbidity and pregnancy outcome data.
Keywords: Prescribing, Medication use, Pregnancy, FDA pregnancy-risk categories
Background
The use of medication in pregnancy is often necessary
for the treatment of acute or chronic illnesses. Poor
management of maternal diseases can have a negative ef-
fect on both the health of the mother and the foetus and
thus medication use is often beneficial. Medication use
may also be inadvertent. It has been reported that up to
half of pregnancies are unplanned [1] and medication
may be prescribed before the general practitioner (GP)
or the patient is aware of the pregnancy.
The prevalence of medication use in pregnancy has
been widely reported, however international estimates
vary from 40-99% [2-8]. Variability in the research meth-
odologies and also in the types of medication used be-
tween countries may contribute to the differences in
reported prevalence [9,10]. Observational research how-
ever has demonstrated that certain medications have the
potential to cause adverse effects to the foetus including
anatomical malformations, impaired physiological func-
tions, alterations to growth, and foetal and infant mortality
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but also delayed subtle effects on social and intellectual
function [11]. The US Food and Drug Administration
(FDA) developed a classification system (Table 1) to cat-
egorise drugs based on foetal-harm risk. The classification
is based on whether there is evidence of harm in human
or animal studies. The majority of drugs have been classi-
fied as category C [12], which indicates a lack of robust
studies assessing human foetal harm, demonstrating the
lack of safety data for the use of many drugs in pregnancy.
Despite this uncertainty, studies have reported high preva-
lence (10-80%) of use of category C drugs [4,6,8]. For cat-
egory D and category X drugs (positive evidence of foetal
harm), studies from various countries such as the US, the
UK, France and Ireland have reported the use of these
medicines by 2.5-59.3% and 0.6-4.6% of pregnant women,
respectively [2,4,6,8,13].
Shortcomings in the clarity of the pregnancy-risk clas-
sifications have led the FDA to initiate a change to the
medicinal-product labelling rules in the US [14]. The
FDA categories are often mistakenly viewed as a grading
classification with increasing risk from A to X and do
not inform on potential harm to the mother from with-
holding treatment [15]. Similar classification systems
exist in Australia and Sweden, however discrepancies be-
tween the three classifications for the same drug bring
into question the usefulness of these systems [16]. The
FDA will soon replace the categories with new pregnancy
risk summary, clinical considerations and data sections,
for both patients and clinicians. They aim to enable pre-
scribers improve benefit-risk assessments of medication
use in pregnancy [17,18].
This is the first study to examine the prevalence of
prescribing to pregnant women in an Irish primary care
setting using the recently established Irish Primary Care
Research Network (IPCRN). Additionally few studies
have examined the prevalence of prescribing throughout
pregnancy using routine data collected in a primary care
setting. Therefore, the overall aim of this study is to es-
tablish the prevalence, patterns and appropriateness of
prescribing during pregnancy in a pilot group of GP
practices affiliated to the Irish Primary Care Research
Network (IPCRN). In the absence of explicit criteria we
have applied the US FDA pregnancy-risk categories as a
proxy measure of prescribing appropriateness in preg-
nancy. The objectives of the study are to 1) establish the
prevalence of prescribing to pregnant women in these
practices using the IPCRN’s Maternity Safe Prescribing
tool and 2) classify the prescribed medications by the
World Health Organisation’s Anatomical Therapeutic
Chemical (ATC) codes and by FDA pregnancy-risk
category.
Methods
Ethics approval for this study was granted by the re-
search ethics committee of the Royal College of Sur-
geons in Ireland. Ethics was obtained for the study and
informed consent was received from the data controller
(the GP).
Study design and setting
This was a retrospective cohort study of pregnant women
attending nine IPCRN-affiliated GP practices located in
the Dublin area. The IPCRN is a national network of GP
practices created through collaboration between the Irish
College of General Practitioners (ICGP), National Univer-
sity of Ireland, Galway (NUIG), and the Royal College of
Surgeons in Ireland (RCSI). It facilitates participating GPs
in the areas of research and audit, enabling them to be-
come involved in planned research trials and providing
them with new software applications to audit and manage
their patient care. Through the IPCRN anonymised GP
practice data can be extracted for research purposes.
Permission to use the anonymised electronic health
Table 1 US Food and Drug Administration Category Definitions
Definition
Category A Controlled studies in women fail to demonstrate a risk to the fetus in the 1st trimester (and there is no
evidence of a risk in later trimesters), and the possibility of fetal harm appears remote.
Category B Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies
in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no
evidence of a risk in later trimesters).
Category C Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other)
and there are no controlled studies in women or studies in women and animals are not available. Drugs
should be given only if the potential benefit justifies the potential risk to the fetus.
Category D There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
disease for which safer drugs cannot be used or are ineffective).
Category X Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal
risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly
outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
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records was obtained from the GP and in agreement with
the IPCRN.
The Irish health care system consists of mixed public
and private funding. Eligibility for primary-care services
consist of General Medical Scheme (GMS) card holders
who are entitled to free medical visits and pay a small
levy for dispensed medications, doctor visit card (DVC)
holders who are entitled to free GP visits but must pay
for prescriptions in full, and private patients (PRV) who
pay for the GP visit and the subsequent dispensed medica-
tions. Eligibility for GMS and DVC cards are by means-
testing based on income [19,20]. All pregnant women in
Ireland however are entitled to a limited number of free
antenatal consultations with the GP and hospital obstetri-
cian or midwife [21].
Participants
An IPCRN software tool identified the patients of inter-
est from the electronically stored medical records of
each GP practice and extracted and uploaded anon-
ymised patient information to a secure IPCRN server.
All female patients who attended these practices for
antenatal care between January 2007 and October 2013
were eligible for inclusion. Patients were excluded if
their date of birth was missing, or if their date of birth
preceded 1960 or if it followed 1996. Patients were also
excluded in cases where both the last menstrual period
(LMP) and estimated date of delivery (EDD) were ab-
sent, or where they equalled each other, or where the re-
corded date of the initial antenatal consultation did not
occur between the LMP and EDD. These records may
have been entered in error or may have been used for
training purposes by the GP. Patients whose LMP pro-
ceeded the study start date (January 2007) or whose EDD
followed the study end-date (October 2013) were ex-
cluded, as full prescription records for the entire antenatal
period would not be available. Pregnancies recorded as
ending in miscarriage were excluded. Duplicate pregnancy
records were also identified and removed.
Data sources and variables
The tool extracted data including year of birth of mother,
patient-payment status (GMS, DVC or PRV), LMP, EDD,
date of initial antenatal consultation and medication pre-
scribed (including date of issue and duration of therapy).
The IPCRN tool also generated a maternity safe prescrib-
ing report for each GP practice including information on
the most commonly prescribed medications within the
practice and any associated pregnancy risk warnings.
Data verification
To ensure the quality and rigour of the IPCRN software
tools, researchers attended the GP practices to confirm
that the data extracted by the tool mapped the correct
patients attending for antenatal care and their related
prescribed medication. The anonymised collated dataset
was also verified by researchers attending the GP prac-
tices to ensure accuracy following data manipulation.
Data extraction
Anonymised information on patients’ demographics,
pregnancy details, and prescriptions were extracted.
Medicines were considered prescribed during the ante-
natal period if the date of issue of the prescription fell
between the LMP and EDD. Prescriptions were labelled
with trimester of issue (defined as three 90 day periods
from the LMP) and whether it was issued prior to the
initial antenatal consultation date. A medicinal product
dictionary was created linking the prescribed brand name
to generic name, ATC code and FDA pregnancy-risk cat-
egory (if available). ATC codes were assigned using the
Irish Pharmacy Union’s monthly drug formulary download
(May 2014) [22]. ‘Briggs: Drugs in Pregnancy and Lactation
(8th edition)’ was used to identify FDA categories [11].
Products containing a combination of active substances
were classified according to the most stringent FDA cat-
egory of the concerned active substances. Medications that
have not been marketed or approved in the US are unclas-
sified. Trimester of use of medication was considered in
cases where the FDA category was dependant on this (e.g.
diclofenac is category B but changes classification to cat-
egory D if used in 3rd trimester or near delivery).
Statistical analysis
Descriptive statistics were used to characterise the pa-
tient population including age (from year of birth to year
of antenatal consultation), patient payment status (GMS,
DVC or PRV) and prevalence of miscarriage. Descriptive
statistics were also used to characterise medications pre-
scribed in pregnancy. The prevalence of prescribing of
any medication during the antenatal period was calculated
excluding Folic Acid. Prevalence of prescribing after the
initial antenatal consultation was also determined. An
additional measure of prevalence excluding all medica-
tions that are also available over-the-counter is reported.
The most commonly prescribed medications are reported,
with each medication counted once per pregnancy in
cases of multiple/repeat prescriptions.
Prescribing prevalence was calculated by patient pay-
ment status. PRV and DVC patients have been grouped
on the basis that they receive non-reimbursable pre-
scriptions. Prescribed medications were categorised per
level one ATC group, an indicator of the nature of pre-
scribing. The FDA categories can be used to determine
the appropriateness of prescribing during pregnancy and
the percentage of pregnancies exposed per FDA category
is reported. Category D and X medications in this report
have been considered potentially harmful and the most
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commonly prescribed medications from these categories
have been reported. Oral contraceptives, fertility treat-
ments and progestogens are category D/X medications,
but are not considered to carry the same risk as other
drugs in these categories [23,24]. These have been classi-
fied separately. Oxytocin is a category X medication used
in the induction of labour and has also been classified
separately. The prevalence of prescribing of category D
and X medication after the initial antenatal consultation
has also been determined.
Logistic regression models were used to model binary
outcome of prescribing during pregnancy and inappropri-
ate prescriptions (category D and X medications, exclud-
ing oral contraceptives, fertility treatments, progestogens
and oxytocin) during pregnancy. Univariate and multivari-
ate logistic regression analysis were used to assess combi-
nations of variables. Likelihood ratio (L-R) tests and Wald
tests were used to validate variable selection for the
model. Model results are presented as odds ratios (OR)
and their corresponding 95% confidence intervals (95%
CI). The model variables were patient age and GMS or
PRV/DVC status.
All statistical analysis was performed using Stata ver-
sion 13 (StataCorp College Station, Texas, USA).
Results
Participants
Data on 2696 patients, representing 3505 pregnancies
were obtained from nine Dublin GP practices affiliated
with the IPCRN. This represented all consultations for
antenatal care in these practices between January 2007
and October 2013.
Data from one practice were subsequently excluded as
it was apparent that prescriptions issued privately (DVC
and PRV patients) from this practice were not recorded
in the electronic medical records from which the pre-
scribing data was extracted. Following the application of
our inclusion criteria, a total of 2361 valid pregnancy re-
cords, representing 1999 women from eight GP prac-
tices, were included in the analysis. Figure 1 describes
the flow of patients through the study.
The average age of participants at time of pregnancy
was 31.6 years (range 16–48 years). The majority of
women in our study were private patients (n = 1476,
73.8%), 474 (23.7%) held a GMS card and 39 women
(2.0%) were DVC holders. Data were missing for 10
patients.
Miscarriage was recorded in 139 pregnancies (5.6%).
The range between practices varied from 1.9%-12.5%.
Data on miscarriage were missing for 41 (1.6%) of
pregnancies.
Prevalence and prescribing patterns during pregnancy
Excluding folic acid 46.8% (n = 1104) of pregnancies were
prescribed at least one medication. Following the initial
consultation for antenatal care 43.9% (n = 1036) of preg-
nancies received a prescription. Excluding any medication
Figure 1 Flowchart of entry of patients into study and exclusion from study. Note: A pregnancy (patient) may be excluded under multiple
exclusion criteria, however the exclusion criteria were applied sequentially to the dataset, and thus an excluded pregnancy (patient) is only
represented once in the flowchart.
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that is available over-the-counter, 40.1% (n = 947) of preg-
nancies were prescribed medication.
Table 2 details the most commonly prescribed medica-
tions overall and by trimester (excluding medication that
is available over-the-counter). The most commonly pre-
scribed medication were amoxicillin and co-amoxiclav
(amoxicillin/clavulanic acid) for treatment of bacterial
infections. This was followed by salbutamol inhalers for
asthma and, oral contraceptives and beclomethasone
inhalers. The most commonly prescribed medications
also available over-the-counter were clotrimazole (top-
ical creams and pessaries) for treatment of candida in-
fections and paracetamol.
Table 3 displays the prevalence of prescribing firstly
excluding folic acid and secondly excluding medication
also available over the counter by patient type. Excluding
medication available over-the-counter and adjusting for
model factors, GMS patients (OR 2.81; 95% CI (2.28,
3.47)) were more likely to have a prescription issued dur-
ing pregnancy than PRV/DVC patients. Table 4 details the
factors associated with prescribing during pregnancy.
Figure 2 details the percentage of pregnancies exposed
to at least one drug from each WHO ATC Level 1 group
category. Over 25% of pregnancies were prescribed an
anti-infective for systemic use such as amoxicillin, co-
amoxiclav, and nitrofurantoin. Alimentary tract and me-
tabolism was the next highest Level 1 group category
which includes antacids, H2-antagonists, proton-pump
inhibitors, laxatives and anti-diabetic medication.
Appropriateness of prescribing
Category A medications (excluding folic acid, vitamins
and minerals) were prescribed to 1.5% (n = 36), category B
to 32.6% (n = 766), category C to 21.6% (n = 510), category
D to 5.9% (n = 140) and category X to 4.9% (n = 116) of
pregnancies. Excluding oral contraceptives, fertility treat-
ments, progestogens and oxytocin, 0.6% (n = 13) of preg-
nancies were prescribed a category X medication. Table 5
details the most commonly prescribed category D and
category X medications and the percentage of pregnancies
exposed to each. Following the initial consultation for
antenatal care 4.7% (n = 110) and 3.1% (n = 72) were
prescribed category D and category X medications (ex-
cluding oral contraceptives, fertility treatments, progesto-
gens and oxytocin; category X 0.4%, n = 10). Category D
medication prescribed following the initial consultation
mainly consisted of anti-depressants, benzodiazepines and
non-steroidal anti-inflammatories.
Adjusting for model factors, inappropriate prescribing
during pregnancy was more likely for patients aged 20–
24 years (OR 2.18; 95% CI (1.12, 4.22)), 35–39 years (OR
2.07; 95% CI (1.16, 3.69)) and aged over 40 years (OR
2.38; 95% CI (1.07, 5.31)) than patients aged 25-29 years
(p < 0.03). GMS patients were more likely to have an in-
appropriate prescription prescribed during pregnancy
than PRV/DVC status patients (OR 2.74; 95% CI (2.84,
4.08); p < 0.001). Table 4 details the results for the fac-
tors associated with inappropriate prescribing during
pregnancy.
Discussion
Key findings
This study used a routine dataset of electronic medical
records extracted from a pilot group of nine GP prac-
tices in the Dublin area. We found that at least one pre-
scription was issued to almost half of the pregnancies
included in the dataset. GMS patients were significantly
more likely to be issued a prescription than private pa-
tients. The most commonly prescribed medications were
systemic anti-infectives (amoxicillin +/− clavulanic acid),
salbutamol inhalers, oral contraceptives and beclometha-
sone inhalers. FDA Category D medications were pre-
scribed in 5.9% of pregnancies and category X medications
in 4.9% of pregnancies. Once oral contraceptives, progesto-
gens, infertility treatments have been excluded the percent-
age of pregnancies prescribed Category X medications
reduced to 0.6%.
Findings in the context of other studies
Various methods including use of pharmacy records, and
patient interview have been used to evaluate maternity
prescribing prevalence and thus comparing results across
studies is difficult. However, a previous Irish study con-
ducted in an out-patient setting examined the prevalence
Table 2 Most commonly prescribed medications during pregnancy (excluding medication available over-the-counter) – the
percentage of pregnancies exposed by trimester and overall
Overall (%) 1st trimester (%) 2nd trimester (%) 3rd trimester (%)
Amoxicillin 11.1 3.6 4.8 4.0
Co-Amoxiclav 8.0 2.3 2.6 3.8
Salbutamol 4.1 1.4 1.7 2.2
Oral Contraceptives 3.3 2.4 0.9 1.2
Beclometasone 2.1 0.6 1.1 0.9
Note: for the overall column each medication is only counted once per pregnancy in cases of repeat or multiple prescriptions that have been issued in different
trimesters.
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of prescribing in pregnancy by patient interview and self-
report [8]. Medication use in early pregnancy (up-to
20 weeks) was assessed and almost 40% reported using a
medication other than folic acid. Category D and X medi-
cations were reported by 2.4% and 0.1% of women respect-
ively (excluding oral contraceptives, fertility treatments and
progestogens). These results are broadly comparable to our
findings. The higher overall prevalence found in our study
can be attributed to prescription data captured throughout
the entire pregnancy, while the higher category D preva-
lence in our study has been inflated by prescription of
diclofenac and mefenamic acid. These are classified as cat-
egory B and C in early pregnancy but when used in the 3rd
trimester are classified as category D. Additionally, in
comparison to studies based on self-report of medica-
tion use, higher prevalence estimates can be found from
prescribing studies as patient adherence to medication
is not accounted for and the additional reluctance of
pregnant women to take prescribed medication due to
fear of potential foetal harm [25].
A UK study similarly examined prescriptions from
general practice during pregnancy, found an overall pre-
scribing prevalence of 65% [2]. The prescription data
captured however includes folic acid and a shorter
period of the pregnancy than our study (90 days prior to
and 70 days after the earliest medical record of preg-
nancy recognition) making it difficult to make compari-
sons to our study.
Studies examining medication use throughout the dur-
ation of pregnancy have also found higher overall preva-
lence (57-99%) [3-6], higher prevalence of category D
medication (3.6-59.3%) but lower prevalence of category
X medication (1.6-4.6%) [4,6,13] in comparison to our
study. Our reported prevalence of category X drugs (4.9%)
however is inflated by hormonal contraceptives and pro-
gestogens, which are largely concentrated in trimester 1
(see Table 2). The low overall prevalence of prescribing
found in our cohort may be a true finding or the result of
differences in data collection with these studies; however
differences in prescribing practices and types of medica-
tion used between countries may contribute to the ob-
served variation [9]. Furthermore prescriptions issued
outside of primary-care (e.g. prescriptions issued directly
from hospital obstetricians) and use of over-the-counter
medications, have not been captured in our study.
The study by Cleary et al. reported that private pa-
tients were more likely to report any medication use [8]
which contrasts with our findings that GMS patients
were more likely to receive a prescription. Certain reim-
bursable over-the-counter and supplement products
Table 3 Prevalence of prescribing excluding folic acid and prevalence of prescribing excluding medication available
over-the-counter by patient-payment type (GMS or PRV/DVC) per pregnancy
Number of valid
pregnancies
Percentage of pregnancies
with a prescription (excluding
folic acid) (%)
Percentage of pregnancies
with a prescription (excluding
OTC medications) (%)
Overall 2361 46.8 40.1
GMS patients 563 69.4 59.1
PRV and DVC patients 1786 39.5 34.0
Table 4 Logistic regression results for the factors associated with any prescription (excluding medication available
over-the-counter) issued during pregnancy and any inappropriate prescription (category D and X medications only,
excluding medication available over-the-counter) issued during pregnancy
Any prescription during pregnancy
(excluding OTC medication)
Any inappropriate prescription during pregnancy
(excluding OTC medication)
Factor Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)
Age
16-19 years 3.47 (1.85,6.52) 2.04* (1.06,3.90) 2.34 (0.76,7.19) 1.44 (0.46,4.48)
20-24 years 1.88* (1.35,2.63) 1.46* (1.03,2.07) 2.81 (1.47,5.39) 2.18* (1.12,4.22)
25-29 years 1.0 1.0 1.0 1.0
30-34 years 1.13 (0.90,1.42) 1.35* (1.07,1.72) 1.09 (0.62,1.91) 1.32 (0.74,2.35)
35-39 years 1.10 (0.86,1.40) 1.34* (1.04,1.74) 1.65 (0.94,2.91) 2.07* (1.16,3.69)
≥40 years 1.66 (1.13,2.44) 1.97** (1.33,2.93) 2.01 (0.91,4.44) 2.38* (1.07,5.31)
Patient status
PRV/DVC 1.0 1.0
GMS 3.48 (2.32,3.42) 2.81** (2.28,3.47) 2.71 (2.32,3.90) 2.74** (2.84,4.08)
*p < 0.03, **p < 0.001.
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(paracetamol, clotrimazole, ferrous fumarate) were pre-
scribed often to GMS patients in our study, but for
which the GP would not prescribe for PRV/DVC pa-
tients. However even when these products were ex-
cluded, the association remained. In addition PRV/DVC
patients receive prescriptions directly from hospital ob-
stetricians, whereas GMS patients, for reimbursement
reasons, have hospital prescriptions transcribed by their
GP. Another potential confounding factor is the differ-
ences in morbidity between the GMS and PRV/DVC
populations, which could not be determined due to the
absence of morbidity data in the IPCRN dataset.
Reductions in overall prescribing and prescribing of Cat-
egory D and Category X were observed following the ini-
tial antenatal consultation, mirroring the trend of many
studies [2,4,13]. In our cohort, category D and X medica-
tions prescribed following the initial consultation mainly
included anti-depressants and benzodiazepines which may
be appropriate in individual circumstances (moderate-to-
severe depression, issues of addiction). It appears pre-
scribers evaluate the risk-benefit of medication use in
pregnancy during the initial antenatal consultation how-
ever there is a high use of potential teratogens in early preg-
nancy, a time period where there is a clear and greater risk
of teratogenic effect [11]. Research has shown that un-
planned pregnancy, socioeconomic group, age, maternal
chronic disease, multiparous pregnancy, and use of a po-
tential teratogen prior to conception affect the mother’s
risk of potential teratogen use in early pregnancy [8,13]. In
our study, GMS status (a proxy indicator for low socioeco-
nomic status) was associated with an increased risk of an
inappropriate prescription.
Strengths and limitations
This is the first study to examine the prevalence of pre-
scribing using data from Irish GP records. Previous studies
that have investigated medication use during pregnancy
have used different methodologies to determine the preva-
lence, including the use of self-report questionnaires or dis-
pensing records and may only examine a particular period
of time, or time-point in pregnancy. This study overcomes
the problem of poor recall in self-report studies through
the use of electronic prescription records and examines
prescription medication use throughout pregnancy. How-
ever, our findings need to be interpreted in the context of
the study limitations.
Firstly, this was a convenience sample of nine General
Practices and the results are not nationally representa-
tive. Secondly the validation process of the collated
IPCRN dataset identified certain issues. These relate to
prescriptions tagged as “cancelled” in the GP’s records
and certain repeat prescriptions issued with a long dur-
ation of therapy beyond normal practice (maximum usu-
ally 6 months). The issues have affected the accuracy of
a small number of individual prescription records within
the IPCRN dataset that have been validated against the
GP’s own records. The issues will be rectified for future
data extraction. Thirdly, gestational length is estimated
in the IPCRN dataset. At time of initial antenatal visit
the GP records the patient’s recall of LMP, and delivery
Figure 2 The percentage of pregnancies exposed by WHO ATC Level 1 Group medication categories.
Table 5 Most common FDA category D medication and
category X medication prescribed
Category D No. of pregnancies
exposed
Category X No. of pregnancies
exposed
Diclofenac* 19 Rosuvastatin 4
Mefenamic acid* 16 Flurazepam 3
Diazepam 15 Atorvastatin 2
Alprazolam 11 Temazepam 2
Prednisolone* 10 Misoprostol 2
Betamethasone* 10 Diclofenac/
Misoprostol
1
Note: each medication is only counted once per pregnancy in cases of repeat
prescriptions or multiple prescriptions issued during the same pregnancy.
*Diclofenac is classified as Category B in 1st and 2nd trimester and Category D
in 3rd trimester. Mefenamic acid is classified as Category C in 1st and 2nd
trimester and Category D in 3rd trimester. Prednisolone and betamethasone
are classified as Category C in 2nd and 3rd trimester and Category D in
1st trimester.
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date is estimated by adding 40 weeks. The occurrence of
a miscarriage was poorly recorded in the IPCRN dataset.
A separate analysis of pregnancies that ended in miscar-
riage could not be performed as the date of the miscar-
riage is not recorded. Additionally a small number of
pregnancies that ended in miscarriage may have been in-
cluded in the analysis if they were not recorded by the
GP. Finally maternal morbidity data and pregnancy out-
come data (stillbirths, congenital anomalies etc.) are not
present in the dataset due to the manner in which they
are currently recorded in Irish GP databases (low levels
of morbidity-coding; hospital delivery letters attached as
scans to electronic medical records). Reliable exposure
data, outcome data and data such as prescription indica-
tion and maternal comorbidity are important aspects of
evaluating medication safety in pregnancy. In many
healthcare databases outcome data are limited and expos-
ure data from prescription or dispensing registries are
often linked to registries containing detailed outcome data
on miscarriage, stillbirth and congenital anomalies [26]. A
similar approach could be considered for the prescription
data contained within the IPCRN database.
Clinical implications and areas for future research
Category D and X medications were considered inappro-
priate for prescribing during pregnancy and the results
show a comparable prevalence of prescribing for these
medications to previous studies and a decrease in pre-
scription following the first visit to the GP for antenatal
care. There is an opportunity to avoid unnecessary use
of potentially harmful drugs in early pregnancy, through
interventions targeted at increasing awareness in women
of childbearing potential but also interventions to aid
prescribers identify women at risk of potential teratogen
use in early pregnancy, prior to the pregnancy. Risk as-
sessments of medication use are needed due to the high
prevalence of medication use in the first trimester. Ar-
ranging the initial antenatal consultation earlier could
also reduce the time period in which a pregnant woman
may be exposed to harmful medication.
The FDA pregnancy classification itself will be soon
eliminated from product literature. Future research should
also focus on the development and validation of explicit
process criteria to examine the appropriateness of pre-
scribing during pregnancy. These criteria will serve to
highlight drugs to be avoided during pregnancy independ-
ent of or in the presence of certain diagnoses.
The IPCRN database can provide useful information
on medicine use and prescribing practices by Irish GPs
in the area of antenatal care. However, absence of data
on patient morbidity and pregnancy outcomes in the
current dataset limits the ability to evaluate the safety of
these medicines. Future research may focus on linking
IPCRN data to alternative sources of outcome data.
Conclusion
The results of the anonymised dataset extracted by the
IPCRN has provided valuable information on the current
practice of antenatal prescribing within this pilot group
of practices and the estimated prevalence is low by com-
parison internationally.
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